SCHEMBL4298159

SCHEMBL4298159

CC(C)(C)OC(=O)N1CCCN(c2cccc(C(=O)O)n2)CC1

nearest known ligand 0.64

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CKS1B P61024 2/20 0.64
SKP1 P63208 2/20 0.64
SKP2 Q13309 2/20 0.64
MAP4K4 O95819 1/20 0.49
PDE10A Q9Y233 1/20 0.48
GPR119 Q8TDV5 3/20 0.47
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
GNE Q9Y223 1/20 0.45
ACHE P22303 1/20 0.44
HRH3 Q9Y5N1 1/20 0.43
GBA1 P04062 1/20 0.43
PTPN11 Q06124 1/20 0.43
PRMT5 O14744 1/20 0.43
ALDH1A1 P00352 1/20 0.43
LMNA P02545 1/20 0.43
MAPT P10636 1/20 0.43
KIF18A Q8NI77 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4295070 0.95 CKS1B (0.61) CKS1BSKP1SKP2MAP4K4GPR119
SCHEMBL20140758 0.86 CKS1B (0.60) CKS1BSKP1SKP2MAP4K4PDE10A
SCHEMBL25233588 0.85 CKS1B (0.58) CKS1BSKP1SKP2MAP4K4GPR119
SCHEMBL461584 0.85 CKS1B (0.62) CKS1BSKP1SKP2MAP4K4GPR119
SCHEMBL1481924 0.85 CKS1B (0.59) CKS1BSKP1SKP2MAP4K4PDE10A
SCHEMBL23104148 0.85 CKS1B (0.59) CKS1BSKP1SKP2MAP4K4PDE10A
SCHEMBL20142337 0.85 CKS1B (0.59) CKS1BSKP1SKP2MAP4K4PDE10A
SCHEMBL461585 0.83 CKS1B (0.60) CKS1BSKP1SKP2MAP4K4GPR119
SCHEMBL3467261 0.82 CKS1B (0.52) CKS1BSKP1SKP2MAP4K4PDE10A
SCHEMBL3467257 0.82 CKS1B (0.52) CKS1BSKP1SKP2MAP4K4PDE10A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2009098576-A1 PYRIDINYL AMIDES FOR THE TREATMENT OF CNS AND METABOLIC DISORDERS PFIZER INC. (US) 2009-08-13 WO disclosed
US-20090197859-A1 Pyridinyl Amides for the Treatment of CNS and Metabolic Disorders PFIZER INC. 2009-08-06 US disclosed
US-20090197859-A1 Pyridinyl Amides for the Treatment of CNS and Metabolic Disorders PFIZER INC. 2009-08-06 US disclosed
US-20090197859-A1 Pyridinyl Amides for the Treatment of CNS and Metabolic Disorders PFIZER INC. 2009-08-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090197859-A1 Pyridinyl Amides for the Treatment of CNS and Metabolic Disorders HTR6, HTR5A, TPH1 CKS1B 2221/4885SKP1 1913/4885SKP2 3726/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.